Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Dysmenorrhea Clinical Trial

Official title:

A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [β-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhea for 24 Weeks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01892904
• Other study ID #: 16114
• Status: Completed
• Phase: Phase 3
• First received: July 2, 2013
• Last updated: September 8, 2015
• Start date: July 2013
• Est. completion date: August 2015

Study information

• Verified date: September 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative study (24-week treatment period).

The objective of this study is to prove the superiority of BAY 86-5300 with flexible extended regimen for treatment of dysmenorrhea to BAY 86-5300 with 28-day cyclic regimen in terms of primary efficacy variable, number of days with dysmenorrheic pain over 140 days of evaluation period.

In addition, the long-term safety of the flexible extended regimen of BAY86-5300 in patients treated for one year will be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. completion date: August 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria: - Dysmenorrhea patients with a total dysmenorrhea score (sum of the two sub-scores: severity of dysmenorrhea and use of analgesics) of at least 3 points in each of the last two menstruations before randomization (baseline observation phase)

• Patients with dysmenorrheic pain during the 2 baseline cycles before randomization. Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with possible radiation towards back or thighs recorded in the Patient Diary in correspondence with a withdrawal and/or menstrual bleeding episode. Pain could start up to 2 days before the onset of the bleeding episode the bleeding and terminates on the last day of bleeding of before

• Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two menses before randomization (baseline observation phase)

• Willingness to use a barrier method (i.e., non-hormonal method) for contraception during the study. Acceptable methods of contraception include (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device.

Exclusion Criteria: - Patients who have organic diseases of which surgical treatment is prioritized by the investigator

• Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in size of the longest diameters

• Patients with ovarian chocolate cysts having solid part in the cyst

• Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dysmenorrhea

Intervention

Drug:
• EE20/DRSP(BAY86-5300)
One tablet [0.02 mg of ethinylestradiol (ß-CDC) and 3 mg of drospirenone] / day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of days with dysmenorrheic pain over 140 days of evaluation period	Number of days with dysmenorrheic pain is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Change in Dysmenorrhea score from baseline to period of withdrawal bleeding	Dysmenorrhea score is a sum of the two sub-scores, severity of dysmenorrhea and use of analgesics, recorded by the participant at every visit	Baseline period (8 weeks before start of treatment) and evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Change of severity of pain Description	The severity of pain is measured by the Visual Analogue Scale (VAS), recorded by the participant at any visit.	Baseline period (8 weeks before start of treatment) and evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period	Number of days with at least moderate dysmenorrheic pain is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period	Number of days with rescue medicine is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period	Number of days with interference of dysmenorrheic pain with daily activity is determined based on daily record of Patient Diary	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days	No
Secondary	Endometrial thickness	Endometrial thickness is the thickest value (mm) of endometrium determined by transvaginal ultrasonography.	24 weeks after taking the initial study medication	No
Secondary	Number of days with bleeding and spotting over treatment phase	Number of days with spotting/bleeding is determined based on daily record of Patient Diary.	Up to 24 weeks	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.